2022
Proteomics Indicates Lactate Dehydrogenase Is Prognostic in Acetaminophen-Induced Acute Liver Failure Patients and Reveals Altered Signaling Pathways
Vazquez JH, Kennon-McGill S, Byrum SD, Mackintosh SG, Jaeschke H, Williams DK, Lee WM, Dranoff JA, McGill MR, Group A. Proteomics Indicates Lactate Dehydrogenase Is Prognostic in Acetaminophen-Induced Acute Liver Failure Patients and Reveals Altered Signaling Pathways. Toxicological Sciences 2022, 187: 25-34. PMID: 35172013, PMCID: PMC9216044, DOI: 10.1093/toxsci/kfac015.Peer-Reviewed Original ResearchConceptsAcute liver failureEnd-stage liver diseaseALF patientsLactate dehydrogenaseLiver diseaseDay 1Acute Liver Failure Study GroupAcute liver failure patientsTransplant-free survivorsKing's College criteriaLiver failure patientsMost clinical laboratoriesFailure patientsLiver failurePrognostic valueControl volunteersAlanine aminotransferaseStudy groupPrognostic potentialPeak injuryDay 3Good biomarkerDay 1 samplesNonsurvivorsPatients
2015
Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014
Torok NJ, Dranoff JA, Schuppan D, Friedman SL. Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology 2015, 62: 627-634. PMID: 25626988, PMCID: PMC4515973, DOI: 10.1002/hep.27720.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsClinical trial designTrial designLiver diseaseLiver fibrosisClinical trialsFuture clinical trial designChronic liver diseaseOff-target toxicityKey unmetPotential off-target toxicityAntifibrotic agentsNoninvasive markerAntifibrotic therapyAntifibrotic drugsPreclinical proofDrug trialsStudy groupRisk populationsPharmacological targetsTrialsExpert overviewFibrosisDiseaseEndpointAmerican Association